Glaxo Group Limited

Christopher J Wallis

Eric W Collington

Peter Hallett

Norman F Hayes

John Bradshaw

Harry Finch

Ian Waterhouse

Alan Naylor

Malcolm Clive Carter

Frank Ellis

Roger F Newton

Alan Wadsworth

David R Marshall

Peter Hallet

A process is described for the preparation of compounds of the formula ##STR1## in which W is C.sub.1-7 alkylene

Preparation of aminocyclopentane acids

Triazine derivatives of formula (I) ##STR1## or salts thereof, wherein

Chemical compounds

Compounds of formula (I) ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, phenylC.sub.1-3 alkoxy (in which the phenyl group is optionally substituted by a substituent selected from halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy and hydroxy), nitro, trifluoromethyl, cyano, --CO.sub.2 R.sup.3 (wherein R.sup.3 is selected from hydrogen and C.sub.1-4 alkyl) and --CONR.sup.4 R.sup.5 (wherein R.sup.4 and R.sup.5 are each independently selected from hydrogen and C.sub.1-4 alkyl, or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a saturated 5- to 7- membered ring, which ring optionally contains one or more groups or atoms selected from oxygen, sulphur, --NH-- and --N(CH.sub.3)--); and R.sup.2 is selected from the group consisting of hydrogen, halogen, hydroxy, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; and salts thereof are inhibitors of the enzyme 5-lipoxygenase. Processes for preparing the compounds of formula (I) and compositions containing them are also described.

Triazine derivatives

Compounds are described of the formula ##STR1## in which R.sup.1 is H, C.sub.1-6 alkyl or C.sub.7-10 aralkyl;

Aminocyclopentanol acids and esters and their preparation and

Compounds are described of the formula ##STR1## where: R.sup.1 is --H or --CH.sub.3,

Aminocyclopentyl ethers and pharmaceutical formulation

Compounds are described of the formulae (1a) and 1b) ##STR1## in which: R.sup.1 is -H, C.sub.1-6 alkyl or C.sub.7-10 aralkyl,

Aminocyclopentanes and their preparation and pharmaceutical formulation

Compounds are described of the formulae (1a) and (1b) ##STR1## in which: --COR.sup.1 is an ester group,

Aminocyclopentane esters and pharmaceutical formulations

Compounds are described of the formula ##STR1## in which --COR.sup.1 is a complex ester or thioester group,

Aminocyclopentane esters and pharmaceutical formulation

Prostanoids are described of the formulae ##STR1## (and the salts thereof) in which: X is cis or trans --CH.dbd.CH-- or CH.sub.2 CH.sub.2 --;

Prostanoid compounds and pharmaceutical formulations

Prostanoids are described of the formulae ##STR1## (and the salts thereof) in which: X is cis or trans--CH.dbd.CH-- or CH.sub.2 CH.sub.2 --;

Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.

Prostanoid compounds and pharmaceutical compositions

Compounds are described of the formula ##STR1## in which R.sup.1 is unsubstituted or substituted phenylalkyl, thienylalkyl or naphthylalkyl, or cinnamyl;

Aminocyclopentanone amides and pharmaceutical formulation

Compounds are described of the formula ##STR1## (and their salts and solvates) in which: X is cis or trans --CH.dbd.CH--;

Growing community of inventors

Royston, United Kingdom

Christopher J Wallis